Status:
COMPLETED
Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers
Lead Sponsor:
Sussex NHS Research Consortium
Collaborating Sponsors:
University of Surrey
Lab 21, Cambridge
Conditions:
Smoking Cessation
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Professor RP Young (Associate Professor of Medicine and Molecular Medicine, School of Biological Sciences, University of Auckland) and his team have developed a reliable genetic test "Respiragene" bas...
Detailed Description
Despite the 5-10% probability of lung cancer in smokers, 50% do not believe they are at significantly increased risk Despite this, over 80% of smokers would like to know their personal risk of lung ca...
Eligibility Criteria
Inclusion
- Aged 20-70 years
- Smoking more than 10 cigarettes daily
Exclusion
- Aged under 20 years or over 70 years
- Smoking less than 10 cigarettes daily
- History of major depression and other psychiatric conditions, dementias and serious or terminal illness (cancers etc.).
- Patients on warfarin would be excluded due to interactions between warfarin and varenicline as varenicline will be used as the modern treatment of choice for smoking cessation.
- Patients who did not wish to have a genetic test would be referred to the practice nurse for smoking cessation.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT01176383
Start Date
September 1 2011
End Date
March 1 2013
Last Update
May 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Integrated Care Partnership The Old Cottage Hospital Alexandra Road,
Epsom, Surrey, United Kingdom, KT17 4BL